Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 68% of modeled bridge. Strengths: Occupancy Rate, Revenue per Bed. Risks: Bed Count, Commercial Payer %. Risk-adjusted uplift: $19.4M (vs $28.4M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $10.8M | $10.8M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $10.4M | $296K | $10.7M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $1.7M | $4.9M | $6.6M | $20.7M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $345K | $345K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 39.1% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $2.7M | $5.4M | $8.1M | $10.8M | $10.8M | $10.8M | $10.8M |
| Denial Rate Reduction | $0 | $2.7M | $5.3M | $8.0M | $10.7M | $10.7M | $10.7M | $10.7M |
| A/R Days Reduction | $0 | $2.2M | $4.4M | $6.6M | $6.6M | $6.6M | $6.6M | $6.6M |
| Clean Claim Rate | $0 | $172K | $345K | $345K | $345K | $345K | $345K | $345K |
| Cumulative | $0 | $7.7M | $15.4M | $23.0M | $28.4M | $28.4M | $28.4M | $28.4M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $28.4M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 44% / 6.1x | 48% / 7.1x | 52% / 8.2x | 54% / 8.7x | 56% / 9.2x |
| 9.0x | 38% / 5.1x | 43% / 6.0x | 47% / 6.9x | 49% / 7.4x | 51% / 7.8x |
| 10.0x | 33% / 4.2x | 38% / 5.1x | 43% / 5.9x | 45% / 6.3x | 46% / 6.7x |
| 11.0x | 29% / 3.5x | 34% / 4.3x | 38% / 5.1x | 40% / 5.4x | 42% / 5.8x |
| 12.0x | 24% / 3.0x | 30% / 3.7x | 34% / 4.4x | 36% / 4.7x | 38% / 5.1x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline -16% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 7.6x, adding 0.9 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $237.1M | — | $237.1M | 44.0% |
| Year 1 | $244.2M | +$18.9M | $263.1M | 48.8% |
| Year 2 | $251.6M | +$28.4M | $279.9M | 51.9% |
| Year 3 | $259.1M | +$28.4M | $287.5M | 53.3% |
| Year 4 | $266.9M | +$28.4M | $295.2M | 54.8% |
| Year 5 | $274.9M | +$28.4M | $303.2M | 56.3% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $5.4M | $8.1M | $10.8M | $12.9M |
| Denial Rate Reductio | $5.3M | $8.0M | $10.7M | $12.8M |
| A/R Days Reduction | $3.3M | $4.9M | $6.6M | $7.9M |
| Clean Claim Rate | $172K | $259K | $345K | $414K |
| Total | $14.2M | $21.3M | $28.4M | $34.0M |
Peer Context — Where This Hospital Sits
Key metrics vs 11 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 44.0% | 8.0% | 12.3% | 26.1% | P80 |
| Net-to-Gross | 19.3% | 33.9% | 36.9% | 39.1% | P0 |
| Occupancy | 56.8% | 47.0% | 64.7% | 72.4% | P36 |
| Rev/Bed | $2.0M | $1.5M | $2.1M | $2.6M | P40 |
| Exp/Bed | $1.1M | $929K | $1.5M | $2.3M | P36 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.